Alpha-1 Antitrypsin Deficiency: The Genetic Lung Disease Hiding in Plain Sight

Imagine developing COPD in your 40s despite never smoking a cigarette. Your doctor runs every test, tries every inhaler, and still can't explain why your lungs are failing decades ahead of schedule. For an estimated 100,000 Americans living with alpha-1 antitrypsin deficiency (AATD), this is reality - and most of them don't even know they have it (Stoller & Aboussouan, 2012).

AATD is one of the most common inherited disorders among people of European descent, yet the average patient waits over 7 years from first symptoms to diagnosis (Campos et al., 2005). A simple genetic test - one that can be done from raw DNA data you may already have - can reveal whether you carry the mutations responsible. Here's what you need to know.

What Is Alpha-1 Antitrypsin and Why Does It Matter?

Alpha-1 antitrypsin (AAT) is a protein made primarily by your liver. Its job is to travel through your bloodstream to your lungs, where it acts as a shield - specifically, it neutralizes an enzyme called neutrophil elastase (Silverman & Sandhaus, 2009).

Think of neutrophil elastase as a microscopic demolition crew. White blood cells release it to break down bacteria and damaged tissue during inflammation. That's useful when you have an infection, but dangerous when there's nothing to stop it. Without enough AAT to keep elastase in check, this enzyme starts digesting healthy lung tissue instead (Lomas & Mahadeva, 2002).

The result? Alveolar walls - the tiny air sacs where oxygen enters your blood - are progressively destroyed. This is the same process behind emphysema, except in AATD it happens earlier in life and without the usual risk factors like smoking (Silverman & Sandhaus, 2009).

The SERPINA1 Gene: Where It All Starts

AAT is encoded by the SERPINA1 gene on chromosome 14. Over 200 variants of this gene have been identified, but two account for more than 95% of clinically significant deficiency cases (Blanco et al., 2006):

• Pi*Z allele (rs28929474, Glu342Lys): The most severe. Each copy reduces AAT levels by roughly 80-85%. Two copies (Pi*ZZ genotype) leave you with only about 10-15% of normal AAT levels (de Serres & Blanco, 2014).
• Pi*S allele (rs17580, Glu264Val): A milder variant. Each copy reduces AAT by about 40%. Homozygous Pi*SS individuals usually produce enough AAT to avoid serious lung disease, though Pi*SZ compounds are at moderate risk (de Serres & Blanco, 2014).

The "Pi" stands for protease inhibitor, the old naming system for AAT variants. The normal allele is called Pi*M - if you have two copies (Pi*MM), your AAT levels are in the healthy range.

Genotype Breakdown and Risk

• Pi*MM: Normal. ~100% AAT levels. No increased risk.
• Pi*MS: Carrier. ~80% AAT levels. Generally no clinical disease.
• Pi*MZ: Carrier. ~60% AAT levels. Slightly increased risk of lung or liver problems, especially with smoking or occupational exposures (Soriano et al., 2022).
• Pi*SS: Mild deficiency. ~60% AAT levels. Low risk of lung disease.
• Pi*SZ: Moderate deficiency. ~35-40% AAT levels. Moderate risk, especially with environmental triggers.
• Pi*ZZ: Severe deficiency. ~10-15% AAT levels. High risk of emphysema, COPD, and liver disease (Strnad et al., 2020).

How Common Is AATD?

AATD is far more prevalent than most people - and many doctors - realize. Among individuals of European descent, the Pi*Z allele has a carrier frequency of roughly 2-3%, meaning about 1 in 25 Northern Europeans carries at least one Z allele (de Serres & Blanco, 2014).

The Pi*ZZ genotype - the severe form - occurs in approximately 1 in 2,000 to 1 in 5,000 individuals of European ancestry. That makes it roughly as common as cystic fibrosis, yet it is diagnosed far less often (Luisetti & Seersholm, 2004).

The Pi*S allele is even more common, with carrier frequencies reaching 10-15% in parts of Southern Europe, particularly the Iberian Peninsula (Blanco et al., 2006).

Globally, an estimated 3.4 million people have Pi*ZZ, Pi*SZ, or Pi*SS genotypes - yet fewer than 10% have been diagnosed (Blanco et al., 2006). This massive gap between expected and identified cases makes AATD one of the most underdiagnosed genetic conditions in the world.

The Two Faces of AATD: Lung and Liver Disease

What makes AATD unusual is that it can damage two entirely different organs through two different mechanisms.

Lung Disease

In the lungs, the problem is too little AAT arriving. Without the protective shield, neutrophil elastase steadily destroys alveolar tissue. This typically manifests as early-onset emphysema, often appearing between ages 30-50 - decades earlier than typical smoking-related COPD (Silverman & Sandhaus, 2009).

About 75% of Pi*ZZ individuals will develop some degree of lung function impairment during their lifetime (Cleveland Clinic, 2024). Smoking dramatically accelerates the process: a Pi*ZZ smoker may develop severe emphysema by their 30s, while a non-smoker with the same genotype may not show symptoms until their 50s or later (Stoller & Aboussouan, 2012).

Liver Disease

In the liver, the problem is the opposite - too much abnormal AAT accumulating. The Z variant causes the AAT protein to misfold and get stuck inside liver cells instead of being secreted into the bloodstream. These protein aggregates trigger inflammation and cell death (Strnad et al., 2020).

Approximately 15% of adults with Pi*ZZ develop clinically significant liver damage, including cirrhosis (American Liver Foundation, 2024). In children, AATD is one of the most common genetic causes of liver disease - about 10% of Pi*ZZ newborns develop liver problems, though most resolve spontaneously (Strnad et al., 2020).

Recent research has also shown that even Pi*MZ heterozygotes have a modestly elevated risk of liver fibrosis and cirrhosis, particularly when combined with other liver insults like alcohol use or metabolic syndrome (Strnad et al., 2020).

Why Does It Take So Long to Diagnose?

The average diagnostic delay for AATD exceeds 7 years from the first appearance of symptoms (Campos et al., 2005). Multiple studies have found that patients typically see three or more doctors and receive at least one incorrect diagnosis - usually asthma or smoking-related COPD - before AATD is identified (Stoller et al., 2005).

Several factors drive this diagnostic gap:

• Symptom overlap: Shortness of breath, wheezing, and chronic cough look identical to asthma or smoking-related COPD.
• Low clinical suspicion: Many physicians don't consider genetic causes of COPD, especially in patients who have ever smoked.
• Rarity bias: Doctors are trained to think of common diagnoses first, and AATD is still perceived as rare despite affecting 1 in 2,000-5,000 people.
• No routine screening: Unlike newborn screening for conditions like PKU or sickle cell disease, AATD testing isn't part of standard panels in most countries.

International guidelines now recommend that all COPD patients be tested for AATD at least once, along with anyone with unexplained liver disease, unexplained bronchiectasis, or a family history of AATD (Miravitlles et al., 2017).

Treatment: What Can Be Done

For Pi*ZZ individuals with documented lung disease, the primary treatment is augmentation therapy - weekly intravenous infusions of AAT protein purified from donated human blood. This raises AAT levels in the lungs to a protective threshold (Miravitlles et al., 2017).

The landmark RAPID trial demonstrated that augmentation therapy significantly slowed the loss of lung tissue as measured by CT densitometry, though it did not show improvements in spirometry or exacerbation rates (Chapman et al., 2015). A multinational registry analysis further showed that augmentation therapy was associated with improved survival in severe AATD patients (Rahaghi et al., 2023).

Beyond augmentation, standard COPD management applies:

• Smoking cessation is the single most impactful intervention for any AATD patient.
• Bronchodilators and inhaled corticosteroids for symptom management.
• Pulmonary rehabilitation for improving exercise capacity.
• Lung transplantation for end-stage disease.

For liver disease, there is currently no specific therapy - management focuses on avoiding alcohol, maintaining a healthy weight, and monitoring for progression. In severe cases, liver transplantation is curative (Strnad et al., 2020).

What You Can Do with Your DNA Data

If you have raw DNA data from 23andMe, AncestryDNA, or another consumer test, you may already have the information needed to check for AATD risk variants. The two key SNPs to look for are:

• rs28929474 (Pi*Z allele) - risk allele: T
• rs17580 (Pi*S allele) - risk allele: T

GenomeInsight can analyze your raw DNA file and flag these variants automatically as part of a comprehensive health and pharmacogenomics report. No data leaves your browser - your DNA is analyzed entirely client-side for maximum privacy.

If your results show you carry one or two copies of the Z or S allele, talk to your doctor about getting a serum AAT level test to confirm your clinical status. Early detection means earlier intervention - and for AATD, that can mean decades of preserved lung function (Stoller & Aboussouan, 2012).

You can also explore our pharmacogenomics reports to see how other genes affect your health, or subscribe to our newsletter for the latest in genomic health research.

Key Takeaways

• Alpha-1 antitrypsin deficiency is one of the most common - yet most underdiagnosed - genetic conditions, affecting roughly 1 in 2,000-5,000 people of European descent.
• It's caused by mutations in the SERPINA1 gene, primarily the Pi*Z and Pi*S alleles.
• AATD can cause early-onset emphysema/COPD (from lack of lung protection) and liver disease (from toxic protein accumulation in liver cells).
• The average diagnostic delay is over 7 years - genetic testing can shortcut this entirely.
• Augmentation therapy can slow lung tissue loss in severe cases, and lifestyle modifications (especially never smoking) dramatically affect outcomes.
• Consumer DNA tests often include the key variants (rs28929474, rs17580) - upload your data to GenomeInsight to check your status.

References

American Liver Foundation. (2024). Alpha-1 antitrypsin deficiency. https://liverfoundation.org/liver-diseases/alpha-1-antitrypsin-deficiency/

Blanco, I., de Serres, F. J., Fernández-Bustillo, E., Lara, B., & Miravitlles, M. (2006). Estimated numbers and prevalence of PIS and PIZ alleles of alpha1-antitrypsin deficiency in European countries. European Respiratory Journal, 27(1), 77–84. https://doi.org/10.1183/09031936.06.00062305

Campos, M. A., Wanner, A., Zhang, G., & Sandhaus, R. A. (2005). Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest, 128(3), 1179–1186. https://doi.org/10.1378/chest.128.3.1179

Chapman, K. R., Burdon, J. G. W., Piitulainen, E., Sandhaus, R. A., Seersholm, N., Stocks, J. M., ... & Stoel, B. C. (2015). Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): A randomised, double-blind, placebo-controlled trial. The Lancet, 386(9991), 360–368. https://doi.org/10.1016/S0140-6736(15)60860-1

de Serres, F. J., & Blanco, I. (2014). Role of alpha-1 antitrypsin in human health and disease. Journal of Internal Medicine, 276(4), 311–335. https://doi.org/10.1111/joim.12239

Lomas, D. A., & Mahadeva, R. (2002). Alpha1-antitrypsin polymerization and the serpinopathies: Pathobiology and prospects for therapy. Journal of Clinical Investigation, 110(11), 1585–1590. https://doi.org/10.1172/JCI0216782

Luisetti, M., & Seersholm, N. (2004). Alpha1-antitrypsin deficiency. 1: Epidemiology of alpha1-antitrypsin deficiency. Thorax, 59(2), 164–169. https://doi.org/10.1136/thorax.2003.006494

Miravitlles, M., Dirksen, A., Ferrarotti, I., Koblizek, V., Lange, P., Mahadeva, R., ... & Stockley, R. A. (2017). European Respiratory Society statement: Diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. European Respiratory Journal, 50(5), 1700610. https://doi.org/10.1183/13993003.00610-2017

Rahaghi, F. F., Monk, R., Engel, T., Engel, C., & Gøtzsche, P. C. (2023). Augmentation therapy for severe alpha-1 antitrypsin deficiency improves survival and is decoupled from spirometric decline. American Journal of Respiratory and Critical Care Medicine, 208(11), 1192–1201. https://doi.org/10.1164/rccm.202305-0863OC

Silverman, E. K., & Sandhaus, R. A. (2009). Alpha1-antitrypsin deficiency. New England Journal of Medicine, 360(26), 2749–2757. https://doi.org/10.1056/NEJMcp0900449

Soriano, J. B., Kendrick, P. J., Paulson, K. R., Gupta, V., Abrams, E. M., Adedoyin, R. A., ... & Vos, T. (2022). Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017. The Lancet Respiratory Medicine, 8(6), 585–596.

Stoller, J. K., & Aboussouan, L. S. (2012). A review of α1-antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine, 185(3), 246–259. https://doi.org/10.1164/rccm.201108-1428CI

Stoller, J. K., Sandhaus, R. A., Turino, G., Dickson, R., Rodgers, K., & Strange, C. (2005). Delay of diagnosis of alpha1-antitrypsin deficiency: A continuing problem. Chest, 128(4), 1989–1994. https://doi.org/10.1378/chest.128.4.1989

Strnad, P., McElvaney, N. G., & Lomas, D. A. (2020). Alpha1-antitrypsin deficiency. New England Journal of Medicine, 382(15), 1443–1455. https://doi.org/10.1056/NEJMra1910234

---

Related Reading

• cystic fibrosis carrier screening
• asthma genetics